| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4: Reisenauer Mark L, Director
Granted 75,364 Stock Option (Right to Buy) |
| 13 Nov 2026 |
Form 3: Reisenauer Mark L, Director
No securities owned |
| 13 Nov 2026 |
Form 4: Feder Julie B, Chief Financial Officer
Granted 164,790 Stock Option (Right to Buy) |
| 13 Nov 2026 |
Form 4: Hari Parameswaran, Chief Medical Officer
Granted 331,173 Stock Option (Right to Buy) |
| 13 Nov 2026 |
Form 4/A: Jagasia Madan, Director
Granted 678,477 Stock Option (Right to Buy) |
| 12 Nov 2026 | 424B3 |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 05 Oct 2026 | SCHEDULE 13G |
| 09 Sep 2026 | EFFECT |
| 28 Aug 2026 | S-1 |
| 14 Aug 2026 |
8-K/A: Financial Statements and Exhibits
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. |
| 14 Aug 2026 | 10-Q |
| 11 Aug 2026 | SCHEDULE 13G |
| 10 Aug 2026 | SCHEDULE 13G |
| 10 Aug 2026 | SCHEDULE 13G |
| 10 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 |
Form 4: Ross Robert W., Director
Granted 37,653 Stock Option (Right to Buy) |
| 05 Aug 2026 |
Form 4: Norkunas Matthew, Director
Granted 37,653 Stock Option (Right to Buy) |
Loading...